{
    "nct_id": "NCT05292222",
    "title": "A Single Arm Study of Resting State Functional Magnetic Resonance Imaging (Rs-fMRI)-Guided Theta Burst Stimulation (TBS) in Early-Stage Alzheimer's Disease (AD)",
    "status": "COMPLETED",
    "last_update_time": "2024-12-17",
    "description_brief": "Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion. AD is functionally characterized by progressive degeneration of large-scale brain networks (LSBNs), including the default mode network (DMN) presumably from the deposition of amyloid plaques and neurofibrillary tangles. Available FDA-approved medications for AD such as donepezil and memantine offer limited benefit and modest impact on quality of life. In combination with resting state functional MRI (rs-fMRI), transcranial magnetic stimulation (TMS) with intermittent theta burst stimulation (iTBS) offers a non-invasive alternative to pharmacotherapy in persons with AD. We propose a pilot trial using rs-fMRI to target dysfunctional LSBNs in early stage AD.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "4 participants screen failed with a low MMSE, 1 participant withdrew before receiving any treatment.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Intermittent Theta Burst Stimulation",
                    "description": "All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.\n\nIntermittent theta burst stimulation: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "10"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "10"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Intermittent Theta Burst Stimulation",
                    "description": "All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.\n\nIntermittent theta burst stimulation: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "10"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "67.6",
                                            "spread": "8.5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ethnicity (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Not Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini Mental Status Examination (MMSE)",
                    "description": "The MMSE measures cognitive and mental status. Total score. Range \\[0-30\\]. Lower score is indicative of more cognitive impairment.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "26.3",
                                            "spread": "1.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Clinical Dementia Rating (CDR) Scale",
                    "description": "The global CDR is a scale used to quantify the severity of dementia symptoms. Range \\[0-3\\]. A higher score is indicative of more severe dementia symptoms.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0.5",
                                            "spread": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Education Level",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Bachelors/Associates",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        }
                                    ]
                                },
                                {
                                    "title": "Masters/PhD",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change in Connectivity Measure of the TGd Parcellations.",
                    "description": "Assessed by calculating the difference and standard deviation between follow-up and baseline of number of abnormal connections of the TGd parcellation. Range: 0-378. There are 378 possible connections of the parcellation. Higher values indicate more abnormal connections of the TGd parcellation pre and post-treatment. The change in the number of abnormal connections of the parcellation is reported.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "abnormal connections",
                    "timeFrame": "9 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Intermittent Theta Burst Stimulation",
                            "description": "All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.\n\nIntermittent theta burst stimulation: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "10"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.5",
                                            "spread": "25"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "9 weeks",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Intermittent Theta Burst Stimulation",
                    "description": "All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.\n\nIntermittent theta burst stimulation: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 10,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 10,
                    "otherNumAffected": 10,
                    "otherNumAtRisk": 10
                }
            ],
            "otherEvents": [
                {
                    "term": "Facial or jaw twitching at RTGd site",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 10
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 10
                        }
                    ]
                },
                {
                    "term": "tearing of the eye",
                    "organSystem": "Eye disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 10
                        }
                    ]
                },
                {
                    "term": "facial twitching at other sites",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 10
                        }
                    ]
                },
                {
                    "term": "Scalp pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 10
                        }
                    ]
                },
                {
                    "term": "Altered consciousness",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "notes": "Happened between treatment days. Participant completed the treatment following evaluation for seizure and cardiac conditions with negative findings.",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 10
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true
            },
            "pointOfContact": {
                "title": "Bhavani Kashyap, MBBS, PhD",
                "organization": "HealthPartners Institute",
                "email": "bhavani.x.kashyap@healthpartners.com",
                "phone": "651-495-6565"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention described is resting-state fMRI\u2013guided intermittent theta-burst stimulation (iTBS), a form of non-invasive transcranial magnetic stimulation (TMS) intended to modulate dysfunctional large-scale brain networks (e.g., the default mode network) in early-stage AD to improve cognition rather than to remove amyloid or tau\u2014i.e., a neuromodulatory cognitive-enhancing approach. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 intervention: rs-fMRI-guided theta burst stimulation (iTBS, a TMS protocol); target: dysfunctional large-scale brain networks/DMN; intended effect: improve cognitive function in early-stage AD (not a biologic or small molecule and not primarily aimed at neuropsychiatric/behavioral symptom reduction). Multiple systematic reviews and RCTs/meta-analyses show TMS/iTBS can produce cognitive improvement in MCI/AD, supporting classification as a cognitive-enhancing neuromodulation. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: The trial does not test a biologic (monoclonal antibody/vaccine) nor a small-molecule drug, and its stated purpose is network-targeted cognitive improvement rather than treating neuropsychiatric symptoms; therefore the best fit among the provided categories is \"cognitive enhancer.\" Note: this is a non-pharmacologic neuromodulation intervention (so no drug/placebo names to report). Supporting literature: systematic reviews/meta-analyses and recent iTBS RCTs document cognitive benefits of TMS/iTBS in MCI/AD. \ue200cite\ue202turn0search5\ue202turn0search2\ue202turn0search4\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The intervention is resting-state fMRI\u2013guided intermittent theta-burst stimulation (iTBS), a non-invasive neuromodulatory TMS protocol intended to modulate dysfunctional large-scale brain networks (e.g., the default mode network) to improve cognition in early Alzheimer's disease. This approach aims to change network function and enhance cognition via plasticity-like mechanisms rather than targeting amyloid, tau, inflammation, or a specific molecular receptor. \ue200cite\ue202turn0search0\ue202turn0search9\ue201",
        "Act: Key extracted details \u2014 intervention: rs\u2011fMRI\u2011guided iTBS (a TMS protocol); proximal biological focus: modulation of large-scale functional networks and synaptic/network plasticity to produce cognitive enhancement (not a biologic or small molecule). Systematic reviews and meta-analyses and recent RCTs support cognitive benefits of TMS/iTBS in MCI/AD, consistent with a synaptic\u2011plasticity/neuroprotection classification. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search7\ue201",
        "Reflect: CADRO categories map neuromodulatory, plasticity\u2011focused cognitive enhancement best to M) Synaptic Plasticity/Neuroprotection. The study is therapeutic (not a diagnostic), non-pharmacologic, and not receptor-, amyloid-, tau-, inflammatory- or vascular-specific; therefore 'M' is the most specific and appropriate CADRO category. If future details showed a parallel molecular target (e.g., a drug combined with TMS) or clear multi-mechanism aims, R) Multi-target could be reconsidered. \ue200cite\ue202turn0search1\ue202turn0search9\ue201",
        "Output: Assigned category \u2014 M) Synaptic Plasticity/Neuroprotection. Explanation: rs\u2011fMRI\u2011guided iTBS is a neuromodulatory cognitive\u2011enhancement intervention whose mechanism is best characterized as modifying network function and promoting synaptic/plasticity\u2011related changes, aligning with CADRO category M. Supporting web search results: Frontiers systematic review/meta\u2011analysis showing larger effects with iTBS and TMS in MCI/AD; large systematic review/meta\u2011analysis showing cognitive benefits of TMS across studies; an RCT reporting delayed cognitive improvement after iTBS; and rs\u2011fMRI/DMN studies describing the network targets used for guidance. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search7\ue202turn0search0\ue201"
    ]
}